- Beacon VP Capital uses a primarily event-driven approach to investing in order to generate returns that are less correlated with the broader financial markets.
- Beacon VP Capital invests primarily in lesser known, micro to mid-cap biotechnology and pharmaceutical companies with pharmaceutical drugs at or near the final stage of the Food and Drug Administration (FDA) approval process.
We use published clinical data to analyze the underlying science of a drug going through the United States Food and Drug Administration (“FDA”) approval process.
- Beacon VP Capital achieves these investment objectives by pursuing an investment strategy focused on scientific analysis, proprietary research and collective intelligence.
- Beacon VP Capital's science based investments consist principally of a combination of securities and derivatives issued by micro to mid-cap biotechnology and pharmaceutical companies primarily operating in the United States.
We screen companies with scheduled FDA events and then apply our research framework to identify drugs that have a high efficacy-to-safety ratio. Our data sources include primary scientific literature, company presentations, and SEC filings.